Toll-like receptors: Activation, signalling and transcriptional modulation

Medzhitov, 2008, Origin and physiological roles of inflammation, Nature, 454, 428, 10.1038/nature07201

Chen, 2010, Sterile inflammation: sensing and reacting to damage, Nat Rev Immunol, 10, 826, 10.1038/nri2873

Takeuchi, 2010, Pattern recognition receptors and inflammation, Cell, 140, 805, 10.1016/j.cell.2010.01.022

Broz, 2013, Newly described pattern recognition receptors team up against intracellular pathogens, Nat Rev Immunol, 13, 551, 10.1038/nri3479

Medzhitov, 2009, Transcriptional control of the inflammatory response, Nat Rev Immunol, 9, 692, 10.1038/nri2634

Latz, 2013, Activation and regulation of the inflammasomes, Nat Rev Immunol, 13, 397, 10.1038/nri3452

O’Neill, 2013, The history of Toll-like receptors – redefining innate immunity, Nat Rev Immunol, 13, 453, 10.1038/nri3446

Chang, 2009, Recent development of the mononuclear phagocyte system: in memory of Metchnikoff and Ehrlich on the 100th anniversary of the 1908 Nobel Prize in Physiology or Medicine, Biol Cell, 101, 709, 10.1042/BC20080227

Anderson, 1985, Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product, Cell, 42, 791, 10.1016/0092-8674(85)90275-2

Lemaitre, 1996, The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults, Cell, 86, 973, 10.1016/S0092-8674(00)80172-5

Michel, 2001, Drosophila Toll is activated by gram-positive bacteria through a circulating peptidoglycan recognition protein, Nature, 414, 756, 10.1038/414756a

Medzhitov, 1997, A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature, 388, 394, 10.1038/41131

Poltorak, 1998, Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene, Science, 282, 2085, 10.1126/science.282.5396.2085

Creagh, 2006, TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity, Trends Immunol, 27, 352, 10.1016/j.it.2006.06.003

Chen, 2015, Toll-like receptor pathways in autoimmune diseases, Clin Rev Allergy Immunol

Netea, 2012, Genetic variation in Toll-like receptors and disease susceptibility, Nat Immunol, 13, 535, 10.1038/ni.2284

Hodgkinson, 2011, Toll-like receptors, their ligands, and atherosclerosis, Sci World J, 11, 437, 10.1100/tsw.2011.36

Broderick, 2015, The inflammasomes and autoinflammatory syndromes, Annu Rev Pathol, 10, 395, 10.1146/annurev-pathol-012414-040431

Thaiss, 2014, The interplay between the innate immune system and the microbiota, Curr Opin Immunol, 26, 41, 10.1016/j.coi.2013.10.016

Gay, 2007, Structure and function of Toll receptors and their ligands, Annu Rev Biochem, 76, 141, 10.1146/annurev.biochem.76.060305.151318

O’Neill, 2008, The interleukin-1 receptor/Toll-like receptor superfamily: 10years of progress, Immunol Rev, 226, 10, 10.1111/j.1600-065X.2008.00701.x

Tabeta, 2006, The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9, Nat Immunol, 7, 156, 10.1038/ni1297

Brinkmann, 2007, The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling, J Cell Biol, 177, 265, 10.1083/jcb.200612056

Pelka, 2014, Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms, J Immunol, 193, 3257, 10.4049/jimmunol.1301886

Barton, 2009, A cell biological view of Toll-like receptor function: regulation through compartmentalization, Nat Rev Immunol, 9, 535, 10.1038/nri2587

Bell, 2005, The molecular structure of the Toll-like receptor 3 ligand-binding domain, Proc Natl Acad Sci USA, 102, 10976, 10.1073/pnas.0505077102

Gay, 2006, Toll-like receptors as molecular switches, Nat Rev Immunol, 6, 693, 10.1038/nri1916

Latz, 2007, Ligand-induced conformational changes allosterically activate Toll-like receptor 9, Nat Immunol, 8, 772, 10.1038/ni1479

Tanji, 2013, Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands, Science, 339, 1426, 10.1126/science.1229159

Stewart, 2010, CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer, Nat Immunol, 11, 155, 10.1038/ni.1836

Takeuchi, 2002, Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins, J Immunol, 169, 10, 10.4049/jimmunol.169.1.10

Takeuchi, 2001, Discrimination of bacterial lipoproteins by Toll-like receptor 6, Int Immunol, 13, 933, 10.1093/intimm/13.7.933

Andrade, 2013, Combined action of nucleic acid-sensing Toll-like receptors and TLR11/TLR12 heterodimers imparts resistance to Toxoplasma gondii in mice, Cell Host Microbe, 13, 42, 10.1016/j.chom.2012.12.003

O’Neill, 2007, The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling, Nat Rev Immunol, 7, 353, 10.1038/nri2079

Carty, 2006, The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling, Nat Immunol, 7, 1074, 10.1038/ni1382

Burns, 1998, MyD88, an adapter protein involved in interleukin-1 signaling, J Biol Chem, 273, 12203, 10.1074/jbc.273.20.12203

Kawai, 1999, Unresponsiveness of MyD88-deficient mice to endotoxin, Immunity, 11, 115, 10.1016/S1074-7613(00)80086-2

Akira, 2003, Role of adapters in Toll-like receptor signalling, Biochem Soc Trans, 31, 637, 10.1042/bst0310637

Fitzgerald, 2001, Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction, Nature, 413, 78, 10.1038/35092578

Horng, 2002, The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors, Nature, 420, 329, 10.1038/nature01180

Dunne, 2003, Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88, J Biol Chem, 278, 41443, 10.1074/jbc.M301742200

Kagan, 2006, Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling, Cell, 125, 943, 10.1016/j.cell.2006.03.047

Bonham, 2014, A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction, Cell, 156, 705, 10.1016/j.cell.2014.01.019

Wesche, 1997, MyD88: an adapter that recruits IRAK to the IL-1 receptor complex, Immunity, 7, 837, 10.1016/S1074-7613(00)80402-1

Flannery, 2010, The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling, Biochem Pharmacol, 80, 1981, 10.1016/j.bcp.2010.06.020

Li, 2002, IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase, Proc Natl Acad Sci USA, 99, 5567, 10.1073/pnas.082100399

Burns, 2003, Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4, J Exp Med, 197, 263, 10.1084/jem.20021790

Medvedev, 2003, Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections, J Exp Med, 198, 521, 10.1084/jem.20030701

Suzuki, 2002, Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4, Nature, 416, 750, 10.1038/nature736

Picard, 2003, Pyogenic bacterial infections in humans with IRAK-4 deficiency, Science, 299, 2076, 10.1126/science.1081902

von Bernuth, 2012, Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans, Eur J Immunol, 42, 3126, 10.1002/eji.201242683

Thomas, 1999, Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase, J Immunol, 163, 978, 10.4049/jimmunol.163.2.978

Kawagoe, 2008, Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2, Nat Immunol, 9, 684, 10.1038/ni.1606

Gay, 2011, What the Myddosome structure tells us about the initiation of innate immunity, Trends Immunol, 32, 104, 10.1016/j.it.2010.12.005

Qian, 2001, IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B, J Biol Chem, 276, 41661, 10.1074/jbc.M102262200

Napetschnig, 2013, Molecular basis of NF-kappaB signaling, Annu Rev Biophys, 42, 443, 10.1146/annurev-biophys-083012-130338

Takaoka, 2005, Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors, Nature, 434, 243, 10.1038/nature03308

Honda, 2004, Role of a transductional–transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling, Proc Natl Acad Sci USA, 101, 15416, 10.1073/pnas.0406933101

Uematsu, 2005, Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction, J Exp Med, 201, 915, 10.1084/jem.20042372

Yamamoto, 2002, Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling, J Immunol, 169, 6668, 10.4049/jimmunol.169.12.6668

Yamamoto, 2003, Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway, Science, 301, 640, 10.1126/science.1087262

Oshiumi, 2003, TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction, Nat Immunol, 4, 161, 10.1038/ni886

Yamamoto, 2003, TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway, Nat Immunol, 4, 1144, 10.1038/ni986

Kagan, 2008, TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta, Nat Immunol, 9, 361, 10.1038/ni1569

Rowe, 2006, The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction, Proc Natl Acad Sci USA, 103, 6299, 10.1073/pnas.0510041103

Zanoni, 2011, CD14 controls the LPS-induced endocytosis of Toll-like receptor 4, Cell, 147, 868, 10.1016/j.cell.2011.09.051

McGettrick, 2010, Localisation and trafficking of Toll-like receptors: an important mode of regulation, Curr Opin Immunol, 22, 20, 10.1016/j.coi.2009.12.002

Sato, 2003, J Immunol, 171, 4304, 10.4049/jimmunol.171.8.4304

Gohda, 2004, Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-beta (TRIF)-dependent pathway in TLR signaling, J Immunol, 173, 2913, 10.4049/jimmunol.173.5.2913

Motshwene, 2009, An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4, J Biol Chem, 284, 25404, 10.1074/jbc.M109.022392

Lin, 2010, Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling, Nature, 465, 885, 10.1038/nature09121

Triantafilou, 2002, Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation, J Cell Sci, 115, 2603, 10.1242/jcs.115.12.2603

Valkov, 2011, Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection, Proc Natl Acad Sci USA, 108, 14879, 10.1073/pnas.1104780108

Ferrao, 2014, IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly, Mol Cell, 55, 891, 10.1016/j.molcel.2014.08.006

Kawagoe, 2007, Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling, J Exp Med, 204, 1013, 10.1084/jem.20061523

De Nardo, 2009, Down-regulation of IRAK-4 is a component of LPS- and CpG DNA-induced tolerance in macrophages, Cell Signal, 21, 246, 10.1016/j.cellsig.2008.10.009

Song, 2009, The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells, Mol Immunol, 46, 1458, 10.1016/j.molimm.2008.12.012

Wesche, 1999, IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family, J Biol Chem, 274, 19403, 10.1074/jbc.274.27.19403

Kobayashi, 2002, IRAK-M is a negative regulator of Toll-like receptor signaling, Cell, 110, 191, 10.1016/S0092-8674(02)00827-9

Zhou, 2013, IRAK-M mediates Toll-like receptor/IL-1R-induced NFkappaB activation and cytokine production, EMBO J, 32, 583, 10.1038/emboj.2013.2

Kagan, 2014, SMOCs: supramolecular organizing centres that control innate immunity, Nat Rev Immunol, 14, 821, 10.1038/nri3757

Ferrao, 2012, Helical assembly in the death domain (DD) superfamily, Curr Opin Struct Biol, 22, 241, 10.1016/j.sbi.2012.02.006

Fernandes-Alnemri, 2007, The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation, Cell Death Differ, 14, 1590, 10.1038/sj.cdd.4402194

Cai, 2014, Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation, Cell, 156, 1207, 10.1016/j.cell.2014.01.063

Lu, 2014, Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes, Cell, 156, 1193, 10.1016/j.cell.2014.02.008

Franklin, 2014, The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation, Nat Immunol, 15, 727, 10.1038/ni.2913

Baroja-Mazo, 2014, The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response, Nat Immunol, 15, 738, 10.1038/ni.2919

Cai, 2014, Prion-like polymerization as a signaling mechanism, Trends Immunol, 35, 622, 10.1016/j.it.2014.10.003

Trinchieri, 2007, Cooperation of Toll-like receptor signals in innate immune defence, Nat Rev Immunol, 7, 179, 10.1038/nri2038

Bafica, 2005, TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis, J Exp Med, 202, 1715, 10.1084/jem.20051782

Bafica, 2006, Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection, J Immunol, 177, 3515, 10.4049/jimmunol.177.6.3515

Moore, 2013, Macrophages in atherosclerosis: a dynamic balance, Nat Rev Immunol, 13, 709, 10.1038/nri3520

Sato, 2000, Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways, J Immunol, 165, 7096, 10.4049/jimmunol.165.12.7096

Dobrovolskaia, 2003, Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR “homotolerance” versus “heterotolerance” on NF-kappa B signaling pathway components, J Immunol, 170, 508, 10.4049/jimmunol.170.1.508

Bagchi, 2007, MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists, J Immunol, 178, 1164, 10.4049/jimmunol.178.2.1164

De Nardo, 2009, Signaling crosstalk during sequential TLR4 and TLR9 activation amplifies the inflammatory response of mouse macrophages, J Immunol, 183, 8110, 10.4049/jimmunol.0901031

Kawai, 2011, Toll-like receptors and their crosstalk with other innate receptors in infection and immunity, Immunity, 34, 637, 10.1016/j.immuni.2011.05.006

Ichinohe, 2010, Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design, Expert Rev Vacc, 9, 1315, 10.1586/erv.10.118

De Nardo, 2014, New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease, Am J Pathol, 184, 42, 10.1016/j.ajpath.2013.09.007

Bauernfeind, 2009, Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression, J Immunol, 183, 787, 10.4049/jimmunol.0901363

Juliana, 2012, Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation, J Biol Chem, 287, 36617, 10.1074/jbc.M112.407130

Fernandes-Alnemri, 2013, Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome, J Immunol, 191, 3995, 10.4049/jimmunol.1301681

Lin, 2014, IRAK-1 bypasses priming and directly links TLRs to rapid NLRP3 inflammasome activation, Proc Natl Acad Sci USA, 111, 775, 10.1073/pnas.1320294111

De Nardo, 2011, NLRP3 inflammasomes link inflammation and metabolic disease, Trends Immunol, 32, 373, 10.1016/j.it.2011.05.004

Sheedy, 2013, CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation, Nat Immunol, 14, 812, 10.1038/ni.2639

Banchereau, 2006, Type I interferon in systemic lupus erythematosus and other autoimmune diseases, Immunity, 25, 383, 10.1016/j.immuni.2006.08.010

Kondo, 2012, Dissecting negative regulation of Toll-like receptor signaling, Trends Immunol, 33, 449, 10.1016/j.it.2012.05.002

Anwar, 2013, Negative regulatory approaches to the attenuation of Toll-like receptor signaling, Exp Mol Med, 45, e11, 10.1038/emm.2013.28

Murray, 2012, Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways, Nat Immunol, 13, 916, 10.1038/ni.2391

O’Neill, 2011, MicroRNAs: the fine-tuners of Toll-like receptor signalling, Nat Rev Immunol, 11, 163, 10.1038/nri2957

Gilchrist, 2006, Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4, Nature, 441, 173, 10.1038/nature04768

Whitmore, 2007, Negative regulation of TLR-signaling pathways by activating transcription factor-3, J Immunol, 179, 3622, 10.4049/jimmunol.179.6.3622

Khuu, 2007, Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages, Mol Immunol, 44, 1598, 10.1016/j.molimm.2006.08.006

Boespflug, 2014, ATF3 is a novel regulator of mouse neutrophil migration, Blood, 123, 2084, 10.1182/blood-2013-06-510909

Cai, 2014, PIKfyve, a class III lipid kinase, is required for TLR-induced type I IFN production via modulation of ATF3, J Immunol, 192, 3383, 10.4049/jimmunol.1302411

De Nardo, 2014, High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3, Nat Immunol, 15, 152, 10.1038/ni.2784

Krebs, 2014, Optimization of transcription factor binding map accuracy utilizing knockout-mouse models, Nucleic Acids Res, 42, 13051, 10.1093/nar/gku1078

Catapano, 2014, HDL in innate and adaptive immunity, Cardiovasc Res, 103, 372, 10.1093/cvr/cvu150

Barter, 2004, Antiinflammatory properties of HDL, Circ Res, 95, 764, 10.1161/01.RES.0000146094.59640.13

Ulevitch, 1978, The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum, J Clin Invest, 62, 1313, 10.1172/JCI109252

Levine, 1993, In vivo protection against endotoxin by plasma high density lipoprotein, Proc Natl Acad Sci USA, 90, 12040, 10.1073/pnas.90.24.12040

Wurfel, 1995, Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein, J Exp Med, 181, 1743, 10.1084/jem.181.5.1743

Xue, 2014, Transcriptome-based network analysis reveals a spectrum model of human macrophage activation, Immunity, 40, 274, 10.1016/j.immuni.2014.01.006

George, 2011, Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly, J Biol Chem, 286, 1341, 10.1074/jbc.M110.159996

Gay, 2014, Assembly and localization of Toll-like receptor signalling complexes, Nat Rev Immunol, 14, 546, 10.1038/nri3713

Li, 2008, IRAK4 in TLR/IL-1R signaling: possible clinical applications, Eur J Immunol, 38, 614, 10.1002/eji.200838161

Cohen, 2009, Targeting protein kinases for the development of anti-inflammatory drugs, Curr Opin Cell Biol, 21, 317, 10.1016/j.ceb.2009.01.015

Chaudhary, 2015, Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (irak4) as a therapeutic target for inflammation and oncology disorders, J Med Chem, 58, 96, 10.1021/jm5016044

Rhyasen, 2015, IRAK signalling in cancer, Br J Cancer, 112, 232, 10.1038/bjc.2014.513

Srivastava, 2012, Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4, Cancer Res, 72, 6209, 10.1158/0008-5472.CAN-12-0337

Ngo, 2011, Oncogenically active MYD88 mutations in human lymphoma, Nature, 470, 115, 10.1038/nature09671

Miyata, 2015, Glucocorticoids suppress inflammation via the upregulation of negative regulator IRAK-M, Nat Commun, 6, 6062, 10.1038/ncomms7062

Khera, 2011, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis, N Engl J Med, 364, 127, 10.1056/NEJMoa1001689

Rohatgi, 2014, HDL cholesterol efflux capacity and incident cardiovascular events, N Engl J Med, 371, 2383, 10.1056/NEJMoa1409065

Rader, 2014, HDL and cardiovascular disease, Lancet, 384, 618, 10.1016/S0140-6736(14)61217-4

Thompson, 2009, ATF3 transcription factor and its emerging roles in immunity and cancer, J Mol Med (Berl), 87, 1053, 10.1007/s00109-009-0520-x

Hai, 2010, ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component?, Gene Expr, 15, 1, 10.3727/105221610X12819686555015